Jim Van Meerten's  Instablog

Jim Van Meerten
Send Message
Jim Van Meerten is an advisor to Marketocracy Capital Management and writes on financial subjects here and on Barchart Portfolio Blogs and Seeking Alpha. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and... More
My company:
Marketocracy capital management
My blog:
Barchart Portfolio Blogs
  • Hospira gives me something to write about 0 comments
    Jul 2, 2010 11:10 AM | about stocks: HSP

    The market hasn't been very kind lately and so there hasn't been a lot to write about. Today while screening on Barchart for stocks hitting new highs I can across Hospira Inc (NYSE:HSP)

    It is a global specialty pharmaceutical and medication delivery company dedicated to advancing wellness by developing, manufacturing and marketing products that help improve the safety and efficacy of patient care. Their portfolio includes one of the industry's broadest lines of generic acute-care injectables, integrated solutions for medication management and infusion therapy, and a full-service contract manufacturing business.

    Generic medicine has a great future as medical care providers attempt to rein in costs. HSP has a generic chemotherapy drug Oxaliplatin that should be a money maker. They now are in the US, Europe and Asia where socialized medicine in some of those countries like generics.

    The stock hit 15 new highs in the last 20 sessions including 4 in the last 5 sessions. Last month the stock increased 10.43% in this soft market. Barchart's technical indicators have 9 buy signals for an overall buy signal of 64%. The stock trades around 57.30 with a 50 day moving average of 53.84.

    The CAPS members on Motley Fool like this stock and vote 120 to 19 that the stock will beat the market with the All Stars voting in agreement 42 to 3. Fool notes that the columnists they follow have positive articles 9 to 0 in favor of this stock.

    Wall Street brokerage analysts give 6 thumbs up will 6 buy recommendations published and 3 other firms are telling their clients to hold 'em if you got 'em. Sales are predicted to increase 4.20% this year and 5.50% next year. Double digit earnings increases of 11.90% this year, 15.20% next year are expected. An 11.60% 5 year compounded annual EPS growth rate of 11.60% will be a welcome sign for the long term.

    The stock has a lot going for it:

    • Already established generic market in the US and expanding into Europe and Asia
    • Recent price momentum with a Barchart Trend Spotter (tm) buy signal
    • Positive investor sentiment
    • Wall Street buy recommendations based on increased sales and double digit EPS growth forecasts

    Jim Van Meerten is an investor who writes on investing here and on Barchart Portfolio Blogs. Please leave a comment below or email JimVanMeerten@gmail.com.



    Disclosure: No psotion at the time of publication
    Stocks: HSP
Back To Jim Van Meerten's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • $MYOK - 100% technical buy signals - 7 New highs and up 32.3% in the last month - Relative Strength Index 77.17%
    about 6 hours ago
  • $EXEL - 80% technical buy signals - 8 new highs and up 31.22% in the last month - Relative Strength Index 76.0%
    1 day ago
  • $ATEN - 100% technical buy signals - 19 new highs and up 38.35% in the last month - Relative Strength Index 85.18%
    4 days ago
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.